{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:35:33Z","timestamp":1793061333657,"version":"4.5.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002253","name":"The Netherland-America Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012639","name":"METAvivor Research and Support Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012639","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"The Susan G Komen Breast Cancer Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA281361"],"award-info":[{"award-number":["R01CA281361"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xcrm.2026.102973","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T14:39:12Z","timestamp":1786027152000},"page":"102973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer"],"prefix":"10.1016","volume":"7","author":[{"given":"Tam Binh V.","family":"Bui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise M.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Bruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah D.W.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Warhadpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirabbas","family":"Parizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Overmoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Lynce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamorna","family":"Brown-Swigart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian L.","family":"Hirst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac J.","family":"Nijman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boudewijn M.T.","family":"Burgering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac S.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Esserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"van \u2018t Veer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-6976","authenticated-orcid":false,"given":"Jennifer M.","family":"Rosenbluth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102973_bib1","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102973_bib2","first-page":"3015","article-title":"Deconstructing the third dimension-how 3D culture microenvironments alter cellular cues","volume":"125","author":"Baker","year":"2012","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.xcrm.2026.102973_bib3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102973_bib4","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/0008-5472.CAN-21-2807","article-title":"Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics","volume":"82","author":"Bhatia","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102973_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","article-title":"Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies","volume":"40","author":"Wolf","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102973_bib6","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102973_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13059-022-02673-3","article-title":"Systematic evaluation of colorectal cancer organoid system by single-cell RNA-Seq analysis","volume":"23","author":"Wang","year":"2022","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2026.102973_bib8","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.3390\/ijms22094322","article-title":"A drug screening pipeline using 2d and 3d patient-derived in vitro models for pre-clinical analysis of therapy response in glioblastoma","volume":"22","author":"Lenin","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102973_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112324","article-title":"Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer","volume":"42","author":"Mertens","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.102973_bib10","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1126\/scitranslmed.aay2574","article-title":"Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients","volume":"11","author":"Ooft","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102973_bib11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s43018-022-00337-6","article-title":"A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology","volume":"3","author":"Guillen","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2026.102973_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101408","article-title":"Fine-Needle Aspiration-Based Patient-Derived Cancer Organoids","volume":"23","author":"Vilgelm","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.xcrm.2026.102973_bib13","doi-asserted-by":"crossref","first-page":"26580","DOI":"10.1073\/pnas.1911273116","article-title":"Pancreatic cancer organoids recapitulate disease and allow personalized drug screening","volume":"116","author":"Driehuis","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102973_bib14","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.celrep.2019.03.088","article-title":"Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma","volume":"27","author":"Saito","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.102973_bib15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","article-title":"Personalized in vitro and in vivo cancer models to guide precision medicine","volume":"7","author":"Pauli","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102973_bib16","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/2472555218766842","article-title":"Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening","volume":"23","author":"Hou","year":"2018","journal-title":"SLAS Discov."},{"key":"10.1016\/j.xcrm.2026.102973_bib17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s42003-019-0305-x","article-title":"A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids","volume":"2","author":"Phan","year":"2019","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xcrm.2026.102973_bib18","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jmcb\/mjaa036","article-title":"Development of a miniaturized 3D organoid culture platform for ultra-high-throughput screening","volume":"12","author":"Du","year":"2020","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.102973_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100212","article-title":"High-throughput drug screening of fine-needle aspiration-derived cancer organoids","volume":"1","author":"Bergdorf","year":"2020","journal-title":"STAR Protoc."},{"key":"10.1016\/j.xcrm.2026.102973_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ph17020225","article-title":"Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug Screening","volume":"17","author":"Rao","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.xcrm.2026.102973_bib21","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.5160","article-title":"An Optimized Protocol for Simultaneous Propagation of Patient-derived Organoids and Matching CAFs","volume":"15","author":"H\u00f6gstr\u00f6m","year":"2025","journal-title":"Bio. Protoc."},{"key":"10.1016\/j.xcrm.2026.102973_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105021","article-title":"Simultaneous isolation of hormone receptor\u2013positive breast cancer organoids and fibroblasts reveals stroma-mediated resistance mechanisms","volume":"299","author":"Hogstrom","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.102973_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13058-024-01798-6","article-title":"Establishing conditions for the generation and maintenance of estrogen receptor-positive organoid models of breast cancer","volume":"26","author":"Oliphant","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102973_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41523-024-00714-7","article-title":"Breast organoid suspension cultures maintain long-term estrogen receptor expression and responsiveness","volume":"10","author":"Chang","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.xcrm.2026.102973_bib25","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1007\/s13577-023-00975-7","article-title":"De-differentiation in cultures of organoids from luminal-type breast cancer is restored by inhibition of NOTCH signaling","volume":"36","author":"Uematsu","year":"2023","journal-title":"Hum. Cell"},{"key":"10.1016\/j.xcrm.2026.102973_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database Hallmark Gene Set Collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.xcrm.2026.102973_bib27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12916-015-0431-3","article-title":"Relevance of tumor-infiltrating lymphocytes in breast cancer","volume":"13","author":"Dushyanthen","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.xcrm.2026.102973_bib28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/bjc.2017.220","article-title":"HYPE or HOPE: The prognostic value of infiltrating immune cells in cancer","volume":"117","author":"Barnes","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102973_bib29","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102973_bib30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-022-06698-x","article-title":"BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance","volume":"195","author":"Kuilman","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2026.102973_bib32","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1158\/1078-0432.CCR-15-2137","article-title":"Phase I study of veliparib (ABT-888) combined with cisplatin and vinorelbine in advanced triple-negative breast cancer and\/or BRCA mutation-associated breast cancer","volume":"22","author":"Rodler","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102973_bib33","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102973_bib34","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","article-title":"Efficacy of neoadjuvant cisplatin in triple-negative breast cancer","volume":"28","author":"Silver","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102973_bib35","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","article-title":"Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy","volume":"28","author":"Byrski","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102973_bib36","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.annonc.2022.01.009","article-title":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102973_bib37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41523-017-0025-7","article-title":"DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib\/carboplatin response in the I-SPY 2 breast cancer trial","volume":"3","author":"Wolf","year":"2017","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.xcrm.2026.102973_bib39","series-title":"RPL24 Ribosomal Protein L24 [ Homo sapiens (Human) ]","year":"2025"},{"key":"10.1016\/j.xcrm.2026.102973_bib40","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.18632\/oncotarget.2099","article-title":"RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth","volume":"5","author":"Wilson-Edell","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2026.102973_bib42","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102973_bib43","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102973_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102973_bib45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41523-025-00741-y","article-title":"Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies","volume":"11","author":"Bar","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.xcrm.2026.102973_bib46","doi-asserted-by":"crossref","first-page":"E309","DOI":"10.1093\/oncolo\/oyad275","article-title":"HER2-Low Status Was Associated With Better Breast Cancer-Specific Survival in Early-Stage Triple-Negative Breast Cancer","volume":"29","author":"Ma","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.xcrm.2026.102973_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088309","article-title":"Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity","volume":"9","author":"Wolf","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102973_bib48","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0006-2952(97)81490-6","article-title":"Oxaliplatin, Tetraplatin, Cisplatin, and Carboplatin: Spectrum of Activity in Drug-Resistant Cell Lines and in the Cell Lines of the National Cancer Institute\u2019s Anticancer Drug Screen Panel","volume":"52","author":"Rixe","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.102973_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1008215213739","article-title":"Carboplatin versus cisplatin in solid tumors: An analysis of the literature","volume":"9","author":"Lokich","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102973_bib50","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1038\/s41467-023-39528-9","article-title":"A landscape of response to drug combinations in non-small cell lung cancer","volume":"14","author":"Nair","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102973_bib51","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.xcrm.2026.102973_bib52","author":"Ianevski"},{"key":"10.1016\/j.xcrm.2026.102973_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-022-00493-z","article-title":"Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II\/III breast cancer","volume":"8","author":"Lang","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.xcrm.2026.102973_bib54","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","article-title":"An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules","volume":"154","author":"Basu","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102973_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1011754","article-title":"Systems approach for congruence and selection of cancer models towards precision medicine","volume":"20","author":"Zou","year":"2024","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.xcrm.2026.102973_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102238","article-title":"Enhancing chemotherapy response prediction via matched colorectal tumor-organoid gene expression analysis and network-based biomarker selection","volume":"52","author":"Zhang","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.xcrm.2026.102973_bib57","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1158\/0008-5472.CAN-24-2758","article-title":"Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies","volume":"86","author":"Ortega-\u00c1lvarez","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102973_bib58","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102973_bib59","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.breast.2010.02.003","article-title":"Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients","volume":"19","author":"Koshy","year":"2010","journal-title":"Breast"},{"key":"10.1016\/j.xcrm.2026.102973_bib60","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ijc.28966","article-title":"Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer","volume":"136","author":"Zhang","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102973_bib61","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1186\/s12885-019-6253-5","article-title":"Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review","volume":"19","author":"Pandy","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xcrm.2026.102973_bib62","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.annonc.2020.08.2064","article-title":"TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker","volume":"31","author":"Mayer","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102973_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000357","article-title":"How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies","volume":"3","author":"Park","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.xcrm.2026.102973_bib64","series-title":"Combination of Olaparib and Navitoclax in Women with HGSC and TNBC","year":"2024"},{"key":"10.1016\/j.xcrm.2026.102973_bib65","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2217\/fon-2021-1450","article-title":"PALVEN: Phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor-and BCL2-positive advanced breast cancer","volume":"18","author":"Muttiah","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.xcrm.2026.102973_bib66","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00109-013-1102-5","article-title":"Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer","volume":"92","author":"Xiang","year":"2014","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.xcrm.2026.102973_bib67","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1158\/1078-0432.CCR-13-2166","article-title":"Preclinical activity profile and therapeutic efficacy of the hsp90 inhibitor ganetespib in triple-negative breast cancer","volume":"20","author":"Proia","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102973_bib68","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3390\/cancers6021031","article-title":"An impermeant ganetespib analog inhibits extracellular Hsp90-mediated cancer cell migration that involves Lysyl oxidase 2-like protein","volume":"6","author":"Mccready","year":"2014","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102973_bib69","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/s41416-020-0993-5","article-title":"Current concepts in tumour-derived organoids","volume":"123","author":"Porter","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102973_bib70","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41435-023-00217-8","article-title":"Reverse translation: the key to increasing the clinical success of immunotherapy?","volume":"24","author":"Vanmeerbeek","year":"2023","journal-title":"Genes Immun."},{"key":"10.1016\/j.xcrm.2026.102973_bib71","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41596-019-0232-9","article-title":"Tumor organoid-T-cell coculture systems","volume":"15","author":"Cattaneo","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2026.102973_bib72","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/nprot.2015.088","article-title":"Efficient genetic engineering of human intestinal organoids using electroporation","volume":"10","author":"Fujii","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2026.102973_bib73","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The Cancer Genome Atlas Pan-Cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2026.102973_bib74","doi-asserted-by":"crossref","first-page":"D966","DOI":"10.1093\/nar\/gkae1078","article-title":"GENCODE 2025: reference gene annotation for human and mouse","volume":"53","author":"Mudge","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.102973_bib75","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1093\/bioinformatics\/bti525","article-title":"BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis","volume":"21","author":"Durinck","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.102973_bib76","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2026.102973_bib77","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/bioinformatics\/btr670","article-title":"Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data","volume":"28","author":"Boeva","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.102973_bib78","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2026.102973_bib79","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.806","article-title":"A framework for variation discovery and genotyping using next-generation DNA sequencing data","volume":"43","author":"DePristo","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2026.102973_bib80","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/bioinformatics\/btv693","article-title":"Genefu: an R\/Bioconductor package for computation of gene expression-based signatures in breast cancer","volume":"32","author":"Gendoo","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.102973_bib81","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/bioinformatics\/btw325","article-title":"GenVisR: Genomic Visualizations in R","volume":"32","author":"Skidmore","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.102973_bib82","author":"Schloerke"},{"key":"10.1016\/j.xcrm.2026.102973_bib83","author":"Horikoshi"},{"key":"10.1016\/j.xcrm.2026.102973_bib84","author":"Wickham"},{"key":"10.1016\/j.xcrm.2026.102973_bib85","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2026.102973_bib86","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2026.102973_bib87","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res."},{"key":"10.1016\/j.xcrm.2026.102973_bib88","author":"Dolgalev"},{"key":"10.1016\/j.xcrm.2026.102973_bib89","author":"Kolde"},{"key":"10.1016\/j.xcrm.2026.102973_bib90","author":"Bolstad"},{"key":"10.1016\/j.xcrm.2026.102973_bib91","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2026.102973_bib92","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2026.102973_bib93","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose-response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.102973_bib94","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/s41596-020-00474-1","article-title":"Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids","volume":"16","author":"Dekkers","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2026.102973_bib95","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/s41467-020-15548-7","article-title":"Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages","volume":"11","author":"Rosenbluth","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102973_bib96","series-title":"Tempus xT Validation Summary","year":"2026"},{"key":"10.1016\/j.xcrm.2026.102973_bib97","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41587-019-0259-z","article-title":"Integrated genomic profiling expands clinical options for patients with cancer","volume":"37","author":"Beaubier","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102973_bib98","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2026.102973_bib99","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.102973_bib102","series-title":"Genomic Data Commons","year":"2025"},{"key":"10.1016\/j.xcrm.2026.102973_bib103","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102973_bib104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102973_bib105","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102973_bib106","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.xcrm.2026.102973_bib107","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/path.2278","article-title":"Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome","volume":"214","author":"Bergamaschi","year":"2008","journal-title":"J. Pathol."},{"key":"10.1016\/j.xcrm.2026.102973_bib108","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10549-016-4041-3","article-title":"Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer","volume":"161","author":"Amara","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2026.102973_bib109","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1186\/1471-2407-10-604","article-title":"Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules","volume":"10","author":"Teschendorff","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xcrm.2026.102973_bib110","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1186\/bcr3035","article-title":"A clinically relevant gene signature in triple negative and basal-like breast cancer","volume":"13","author":"Rody","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102973_bib111","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1471-2164-7-115","article-title":"Cell-type specific gene expression profiles of leukocytes in human peripheral blood","volume":"7","author":"Palmer","year":"2006","journal-title":"BMC Genom."},{"key":"10.1016\/j.xcrm.2026.102973_bib112","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","article-title":"Gene expression markers of Tumor Infiltrating Leukocytes","volume":"5","author":"Danaher","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102973_bib113","doi-asserted-by":"crossref","first-page":"R86","DOI":"10.1186\/bcr3481","article-title":"Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers","volume":"15","author":"Bianchini","year":"2013","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102973_bib114","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/bcr2234","article-title":"T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers","volume":"11","author":"Rody","year":"2009","journal-title":"Breast Cancer Res."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:26:22Z","timestamp":1793060782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126003903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":109,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666379126003903"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102973","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102973","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102973"}}